Drug
Ferinject
Ferinject: highest development phase Post-Market, developed by Vifor Pharma. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Vifor Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ferinject NCT01110356 | Post-Market | Iron Deficiency |
| Ferinject 50 mg/ml NCT01345968 | Post-Market | Anemia |
| Ferinject NCT01975272 | Post-Market | Postoperative Anaemia |
| Ferinject ® NCT00706667 | Post-Market | Iron Deficiency Anemia |
| Ferinject (ferric carboxymaltose) NCT01453608 | Post-Market | Iron Deficiency |
| Ferinject (ferric carboxymaltose) NCT01394562 | Phase 3 | Iron Deficiency |
| Ferinject ® (Ferric carboxymaltose) NCT00821717 | Phase 3 | Chronic Heart Failure |
| FERINJECT® (Ferric carboxymaltose) NCT00882414 | Phase 2 | Thrombocytosis |
Latest
No recent events.
Follow Ferinject on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.